Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
Revenue (TTM)
$9 Mln
Net Profit (TTM)
$0 Mln
ROE
-29.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.3
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$0
EPS
$-0.1
Face value
--
Shares outstanding
39,978,693
CFO
$-343.27 Mln
EBITDA
$-355.11 Mln
Net Profit
$-454.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
| -44.3 | -51.8 | -44.3 | -62.3 | -64.1 | -70.3 | -43.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
| -67.7 | -75.7 | 15.9 | -88.4 | -41.9 | 381.8 | 146.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Curis (CRIS)
|
0.5 | 20.5 | 9.4 | -7.6 | -358.0 | 2829.1 | -- | 4.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase... inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Address: Building C, Lexington, MA, United States, 02421 Read more
President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Curis Inc (CRIS) is $0.55 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Curis Inc (CRIS) has given a return of -64.14% in the last 3 years.
Since, TTM earnings of Curis Inc (CRIS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-17.14
|
23.79
|
|
2024
|
-0.54
|
-3.91
|
|
2023
|
-1.55
|
3.74
|
|
2022
|
-0.04
|
0.06
|
|
2021
|
-0.48
|
0.24
|
The 52-week high and low of Curis Inc (CRIS) are Rs 3.13 and Rs 0.50 as of 04-Apr-2026.
Curis Inc (CRIS) has a market capitalisation of $ 20 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Curis Inc (CRIS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.